0001193805-24-000325.txt : 20240306
0001193805-24-000325.hdr.sgml : 20240306
20240306215218
ACCESSION NUMBER: 0001193805-24-000325
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240304
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOWSON TAMAR D
CENTRAL INDEX KEY: 0001202286
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36201
FILM NUMBER: 24727985
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNIC, INC.
CENTRAL INDEX KEY: 0001280776
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 562358443
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1200 AVENUE OF THE AMERICAS
STREET 2: SUITE 200
CITY: NEW YORK
STATE: X1
ZIP: 10036
BUSINESS PHONE: (332) 255-9818
MAIL ADDRESS:
STREET 1: 1200 AVENUE OF THE AMERICAS
STREET 2: SUITE 200
CITY: NEW YORK
STATE: X1
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: VITAL THERAPIES INC
DATE OF NAME CHANGE: 20040219
4
1
e619339_4-howson.xml
X0508
4
2024-03-04
0
0001280776
IMMUNIC, INC.
IMUX
0001202286
HOWSON TAMAR D
1200 AVENUE OF THE AMERICAS, SUITE 200
NEW YORK
NY
10036
1
0
0
0
0
Stock Option
9.5400
2024-03-04
4
D
0
19973
D
2029-10-11
Common Stock
19973
0
D
Stock Option
9.5400
2024-03-04
4
D
0
9986
D
2029-10-11
Common Stock
9986
0
D
Stock Option
12.3000
2024-03-04
4
D
0
15000
D
2030-07-02
Common Stock
15000
0
D
Stock Option
14.7700
2024-03-04
4
D
0
10000
D
2031-06-10
Common Stock
10000
0
D
Stock Option
3.4000
2024-03-04
4
D
0
10000
D
2032-06-15
Common Stock
10000
0
D
Stock Option
1.72
2024-03-04
4
A
0
64959
A
Common Stock
64959
64959
D
On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.
/s/ Tamar Howson
2024-03-06